Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.

ABSTRACT:

Background

Although the clinical validity of risk-associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk-associated SNPs raises concern that it is premature for clinical use. Our objective is to assess the degree and impact of risk reclassification with the increasing number of SNPs.

Methods

A total of 3239 patients from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial were included. Four genetic risk scores (GRSs) were calculated based on sets of sequentially discovered prostate cancer (PCa) risk-associated SNPs (17, 34, 51, and 68 SNPs).

Results

Pair-wise correlation coefficients between sets of GRSs increased a

SUBMITTER: Chen H 

PROVIDER: S-EPMC6949015 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature